Valneva SE

Valneva and Pfizer Report Further Positive Phase 2 Booster Results for Lyme Disease Vaccine Candidate

02 Sep 2024 22:00:00 By Nasdaq GlobeNewswire

Valneva Reports Half Year 2024 Financial Results and Provides Corporate Updates

12 Aug 2024 22:00:00 By Nasdaq GlobeNewswire

VALNEVA - Declaration of shares and voting rights: July 31, 2024

05 Aug 2024 23:30:00 By Nasdaq GlobeNewswire

Valneva and LimmaTech Enter into a Strategic Partnership to Accelerate the Development of the World’s Most Clinically Advanced Tetravalent Shigella Vaccine Candidate

31 Jul 2024 22:00:00 By Nasdaq GlobeNewswire

CEPI Expands Partnership with Valneva with a $41.3 Million Grant to Support Broader Access to the World’s First Chikungunya Vaccine

21 Jul 2024 22:00:00 By Nasdaq GlobeNewswire

Phase 3 VALOR Lyme Disease Trial: Valneva and Pfizer Announce Primary Vaccination Series Completion  

17 Jul 2024 13:00:00 By Nasdaq GlobeNewswire

Declaration of shares and voting rights - Valneva SE - June 30, 2024

04 Jul 2024 09:00:00 By Nasdaq GlobeNewswire

Valneva Receives Marketing Authorization in Europe for the World’s First Chikungunya Vaccine, IXCHIQ®

30 Jun 2024 22:00:00 By Nasdaq GlobeNewswire

Valneva Announces Successful Outcome of its Combined General Meeting and Appointment of a New Director to its Board

26 Jun 2024 08:45:00 By Nasdaq GlobeNewswire

Valneva Announces Health Canada Approval of the World’s First Chikungunya Vaccine, IXCHIQ®

23 Jun 2024 22:00:00 By Nasdaq GlobeNewswire

Valneva Announces Availability of Documentation for its Combined Shareholder Meeting and Provides Corporate Update

04 Jun 2024 22:00:00 By Nasdaq GlobeNewswire

VALNEVA - Declaration of shares and voting rights: May 31, 2024

04 Jun 2024 09:00:00 By Nasdaq GlobeNewswire

Valneva to Present and Hold Investor Meetings at Upcoming Conferences in June

04 Jun 2024 08:35:00 By Nasdaq GlobeNewswire

Valneva Announces Publication of Lyme Disease Phase 2 Trials in the Lancet Infectious Diseases

03 Jun 2024 08:35:00 By Nasdaq GlobeNewswire

Valneva Receives EMA’s Positive CHMP Opinion for its Chikungunya Vaccine

31 May 2024 08:35:00 By Nasdaq GlobeNewswire

Valneva Appoints Dr. Hanneke Schuitemaker, Ph.D. as Chief Scientific Officer

20 May 2024 22:00:00 By Nasdaq GlobeNewswire

Valneva Reports Further Positive Pivotal Phase 3 Data in Adolescents for its Single-Shot Chikungunya Vaccine

12 May 2024 22:00:00 By Nasdaq GlobeNewswire

Valneva Reports First Quarter 2024 Financial Results and Provides Corporate Updates

06 May 2024 22:00:00 By Nasdaq GlobeNewswire

Declaration of shares and voting rights April 30, 2024 - VALNEVA SE

05 May 2024 22:30:00 By Nasdaq GlobeNewswire

Declaration of voting rights - Valneva SE, March 2024

04 Apr 2024 09:00:00 By Nasdaq GlobeNewswire